PFC Therapeutics

PFC Therapeutics is a clinical-stage biotechnology company focused on developing perfluorocarbon-based oxygen carriers for the treatment of acute ischemic conditions. The company's lead candidate, Oxycyte, is a third-generation perfluorocarbon emulsion designed to enhance oxygen delivery to tissues at risk of hypoxia, such as in traumatic brain injury and decompression sickness. By utilizing the high gas-solubility properties of perfluorocarbons, PFC Therapeutics aims to provide a synthetic alternative to blood-based oxygen transport. The company targets critical care indications where rapid restoration of oxygenation is vital for patient survival and recovery. Its technology platform is based on the unique physical properties of perfluorocarbons, which allow for efficient gas exchange in the microcirculation.